You are here

  • Home
  • Online First
  • Nerve biopsy in T-cell lymphoma with neurolymphomatosis: where and when

Article Text

Article menu
Download PDFPDF
Neurological rarities
Nerve biopsy in T-cell lymphoma with neurolymphomatosis: where and when
  1. Menelaos Pipis1,2,
  2. Zane Jaunmuktane3,4,
  3. Teresa Marafioti5,
  4. Sebastian Brandner3,6,
  5. Elaine C Smith7,
  6. Shirley D'Sa8,
  7. Michael P Lunn1,
  8. Kate Cwynarski8,
  9. Doreen Fialho9,
  10. Sachit Shah10,
  11. Geraint N Fuller11,
  12. Mary M Reilly1
  1. 1Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
  2. 2Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  3. 3Department of Neuropathology, The National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK
  4. 4Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
  5. 5Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK
  6. 6Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
  7. 7Department of Rheumatology, Cheltenham General Hospital, Cheltenham, UK
  8. 8Department of Clinical Haematology, UCLH NHS Foundation Trust, London, UK
  9. 9Department of Clinical Neurophysiology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  10. 10Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, UK
  11. 11Department of Neurology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK
  1. Correspondence to Professor Mary M Reilly, Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK; m.reilly{at}ucl.ac.uk

Abstract

Peripheral T-cell lymphomas are rare heterogeneous haematological malignancies that may also involve peripheral nerves in a very small subset of cases. We report a patient with a diagnostically challenging cutaneous T-cell lymphoma and multifocal mononeuropathies in whom a targeted nerve biopsy identified lymphomatous infiltration of nerves and expedited combination treatment with chemotherapy and an autologous stem cell transplant. She showed an excellent response with a complete metabolic response on positron emission tomography imaging and significant clinical improvement, maintained 5 years post-treatment.

  • CLINICAL NEUROLOGY
  • HAEMATOLOGY
  • PERIPHERAL NEUROPATHOLOGY

Data availability statement

Data are available on reasonable request.

https://doi.org/10.1136/pn-2023-003992

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available on reasonable request.

    View Full Text

    Footnotes

    • Twitter @mike_the_nerve

    • Contributors MP: major role in the acquisition of data, drafting, revising and finalising the manuscript for content. ZJ, TM, SB and MPL: acquisition of data, interpretation and presentation of pathological findings, review and critique of the manuscript. KC, ECS and SD'S: acquisition of data, responsible consultants for patient’s care and subsequent treatment, review and critique of the manuscript. SS and DF: acquisition of data, interpretation and presentation of radiological and neurophysiological findings, review and critique of the manuscript. GNF and MMR: major acquisition of data, responsible consultants for patient’s care, conceptualisation of the study, revising and finalising the manuscript for content.

    • Funding MP is funded by the NIH and the Inherited Neuropathy Consortium (INC; grant U54NS065712) as well as the BMA (Vera Down grant; no grant number). MMR is grateful to the Medical Research Council (MRC MR/S005021/1), the National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712 and 1UOINS109403-01 and R21TR003034), Muscular Dystrophy Association (MDA510281) and the Charcot Marie Tooth Association (CMTA) for their support. ZJ and SB are supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed by Gareth Llewelyn, Newport, UK.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

    Other content recommended for you